PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Both companies show declining cash positions (-13.21% vs TRAW's -11.71%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Cash + STI yoy 1.25-1.5x TRAW's -11.71%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Other current assets growth < half of TRAW's 70.00%. David Dodd sees a leaner approach to short-term items.
-11.17%
Similar yoy growth to TRAW's -10.95%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
7.73%
Below half TRAW's -12.50%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Below half of TRAW's -12.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Similar yoy to TRAW's -10.95%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
-100.00%
Less than half of TRAW's 26.84%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
1577.51%
Exceeding 1.5x TRAW's 22.79%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-26.01%
Less than half of TRAW's 14.64%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of TRAW's -1.86%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
Less than half of TRAW's 10.14%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
≥ 1.5x TRAW's -1.25%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Above 1.5x TRAW's 18.18%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
0.5-0.75x TRAW's -19.19%. Martin Whitman is wary of lagging equity growth vs. competitor.
-10.65%
Similar yoy to TRAW's -10.95%. Walter Schloss sees parallel expansions in total capital.
-100.00%
Both TRAW and the company show zero Total Investments Growth.
-4.69%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
13.42%
1.1-1.25x TRAW's 11.71%. Bill Ackman questions if net debt is increasing faster than competitor.